- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | BiomX: Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems | 3 | GlobeNewswire (USA) | ||
| 13.04. | BiomX Accelerates Defense Technology Buildout with DFSL Acquisition | 261 | GlobeNewswire (Europe) | NETANYA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE: PHGE) ("BiomX" or the "Company") today announced that it has accelerated the exercise of its previously disclosed exclusive option... ► Artikel lesen | |
| 13.04. | BiomX: Acquisition Of Zorronet Expands Into AI-Driven Defense And Security Command Systems | 1 | pulse2.com | ||
| 10.04. | BiomX Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 10.04. | T3 Defense verkauft ZorroNet an BiomX in Aktie-und-Cash-Deal | 5 | Investing.com Deutsch | ||
| 10.04. | BiomX completes acquisition of AI defense software firm Zorronet | 1 | Investing.com | ||
| 10.04. | BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications | 479 | GlobeNewswire (Europe) | NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the "Company") today announced that it has completed the acquisition of 100% of Zorronet from... ► Artikel lesen | |
| 10.04. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | BiomX kündigt Übernahme von DFSL an und schwenkt auf Verteidigungssektor um | 10 | Investing.com Deutsch | ||
| 31.03. | BiomX to acquire laser detection firm DFSL in defense pivot | 1 | Investing.com | ||
| 31.03. | BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System | 296 | GlobeNewswire (Europe) | NETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of proprietary... ► Artikel lesen | |
| 30.03. | BiomX Adds Former Mossad Deputy to Advisory Board | 1 | GlobeNewswire (USA) | ||
| 27.03. | BiomX: Delisting-Gefahr an der NYSE American wegen Eigenkapitalmängeln | 1 | Investing.com Deutsch | ||
| 27.03. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.03. | BiomX receives NYSE American non-compliance notice | 2 | Seeking Alpha | ||
| 27.03. | BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency | 166 | GlobeNewswire (Europe) | NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the "Company") today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American... ► Artikel lesen | |
| 26.03. | BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations | 147 | GlobeNewswire (Europe) | NETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) today announced the launch of X Security & Defense LTD., a new wholly-owned subsidiary. The company will finance... ► Artikel lesen | |
| 19.03. | Phage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sector | 2 | FierceBiotech | ||
| 19.03. | BiomX CEO Issues Letter to Stockholders | 213 | PR Newswire | CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities
... ► Artikel lesen | |
| 19.03. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| AMGEN | 295,40 | +0,44 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,008 | +3,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,324 | -1,52 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Grant of Restricted Stock Units | Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,331 | -0,37 % | PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing | MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,200 | +0,67 % | Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley - Cardiol Therapeutics | ||
| REDHILL BIOPHARMA | 1,025 | +1,49 % | RedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of... ► Artikel lesen | |
| KYNTRA BIO | 6,150 | +1,65 % | Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 11,100 | 0,00 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results | LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology... ► Artikel lesen | |
| LEXAGENE | - | - | NEINOR HOMES, S.A.: Additional information on joint-venture agreement with Stoneshield Capital | ||
| VAXCYTE | 52,00 | +1,96 % | Vaxcyte, Inc.: Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults | OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 5,400 | -9,55 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology ... | WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics | NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the sale of its immuno-oncology related assets, consisting... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 6,385 | -0,31 % | Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels | ||
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report |
Das Unternehmen BIOMX INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,220 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.